These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 20148650

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H.
    Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
    [Abstract] [Full Text] [Related]

  • 43. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
    Krohne TU, Muether PS, Stratmann NK, Holz FG, Kirchhof B, Meyer CH, Fauser S.
    Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial.
    Lai TY, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS.
    Retina; 2009 Oct; 29(9):1218-26. PubMed ID: 19934816
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP, Bhat PV, Foster CS.
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection.
    Lee TW, Robinson JR.
    J Ocul Pharmacol Ther; 2001 Dec; 17(6):565-72. PubMed ID: 11777180
    [Abstract] [Full Text] [Related]

  • 53. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.
    Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, Park KH.
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):612-8. PubMed ID: 23735192
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC, Kang IS, Lee SH, Yoon KC.
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.